Cagrilintide + Retatrutide Stack Protocol - Amylin + Triple Agonist

Cagrilintide + Retatrutide Stack Quick Reference

What Is the Cagrilintide + Retatrutide Stack?

The cagrilintide + retatrutide stack is a community-derived 4-receptor weight-management protocol that combines cagrilintide (a long-acting amylin/calcitonin receptor agonist) with retatrutide (a triple GLP-1/GIP/glucagon receptor agonist). The combination targets amylin receptors and calcitonin receptor via cagrilintide, plus GLP-1, GIP, and glucagon receptors via retatrutide. No other current peptide stack covers this breadth of metabolic pathway activation.

The rationale extends the CagriSema model, where adding amylin agonism to GLP-1 agonism produced additive weight loss (20.4% in REDEFINE 1 vs 14.9% semaglutide alone). This stack replaces semaglutide's single-target GLP-1 profile with retatrutide's triple agonism, aiming to add GIP-driven metabolic efficiency and glucagon-driven energy expenditure on top of amylin + GLP-1 synergy.

No direct clinical trial has evaluated cagrilintide + retatrutide. Protocols are extrapolated from individual component evidence, including REDEFINE data for cagrilintide and TRIUMPH data for retatrutide. This is one of the most speculative cagrilintide-combination protocols on the site, and the combined GI burden is a major practical concern.

Why Add Cagrilintide to Retatrutide?

Triple Agonist Foundation - What Retatrutide Already Provides

Retatrutide alone is the most potent single-agent weight-loss peptide in clinical development, with reported mean weight loss up to 28.7% at 68 weeks in TRIUMPH-4. It combines GLP-1 receptor activation (appetite suppression and gastric-emptying delay), GIP receptor activation (metabolic efficiency and insulin-sensitivity support), and glucagon receptor activation (energy expenditure and fat-oxidation support). See the full retatrutide protocol page for monotherapy context.

The Missing Pathway - Brainstem Amylin Satiety

Retatrutide does not activate amylin receptors. Cagrilintide does, including receptor signaling in hindbrain satiety regions that are distinct from GLP-1 appetite pathways. The stack hypothesis is that adding amylin signaling to retatrutide's triple agonism may amplify satiety via non-overlapping neural routes.

Complementary Gastric Emptying - Triple-Source Delay

Cagrilintide and retatrutide both delay gastric emptying through independent receptor mechanisms. The convergent effect may enhance fullness but can also increase nausea, vomiting, constipation, and escalation intolerance.

Glucagon + Amylin - Dual Glucagon Modulation

Retatrutide uses direct glucagon-receptor agonism, while cagrilintide has calcitonin-receptor-linked effects that can modulate glucagon signaling differently. Their net combined impact on glucose homeostasis remains uncharacterized.

Cagrilintide + Retatrutide Dosing Protocol & Schedule

Format A: Separate Vials - Staggered Co-Titration

This is the recommended format. Start retatrutide first, then add cagrilintide after GI tolerance is established to reduce compounded nausea and gastric-motility effects.

Format B: Pre-Blended Vial (12.5 mg + 2.5 mg)

Some suppliers list a fixed 5:1 pre-blend (12.5 mg retatrutide + 2.5 mg cagrilintide). This format simplifies handling but prevents independent titration.

Protocol Notes

• Injection logistics: Both compounds are subcutaneous and typically once weekly. Use different injection sites on the same day.
• Oral options: Neither compound is orally bioavailable in these formulations.
• GI management is critical: Slow titration, protein-forward meals, hydration, and lower-fat meals during escalation are commonly used mitigation strategies.
• Do not combine with semaglutide or tirzepatide: Retatrutide already carries GLP-1 activity (plus GIP and glucagon), so overlap increases redundancy and tolerability burden.
• Dysesthesia monitoring: Retatrutide dose escalation has been associated with tingling, numbness, or prickling sensations in clinical programs.

Cagrilintide + Retatrutide Reconstitution Guide

Format A: Separate Vials

Math verification (Retatrutide 10 mg vial, 1.0 mL BAC): concentration = 10,000 mcg/mL. 8 mg dose = 0.80 mL (80 units). 12 mg dose = 1.20 mL (120 units).

Math verification (Cagrilintide 5 mg vial, 2.0 mL BAC): concentration = 2,500 mcg/mL. 2.4 mg dose = 0.96 mL (96 units).

7-Step Reconstitution Instructions

1. Allow vial(s) to reach room temperature for 10-15 minutes.
2. Swab stoppers with alcohol and let them dry.
3. Draw BAC water volume according to target table.
4. Inject BAC water slowly down vial wall (especially important for cagrilintide).
5. Gently swirl/roll to dissolve; do not shake.
6. Confirm solution clarity; discard cloudy or particulate solutions.
7. Label compound, concentration, and date; refrigerate immediately at 2-8 C and use within 28-30 days.

Cagrilintide + Retatrutide Side Effects & Safety

This combination has not been tested directly in a clinical trial. Safety expectations are extrapolated from single-agent profiles. The primary concern is compounded GI burden from two potent appetite-suppressive compounds that both slow gastric emptying through different receptor pathways.

• Amplified GI effects: Both compounds independently carry high rates of nausea, vomiting, diarrhea, and constipation, with highest burden during weeks 9-24 when both are escalating.
• Dysesthesia (retatrutide-specific): Tingling, numbness, or prickling has been reported in retatrutide trials and appears dose-related.
• Injection-site reactions: More commonly associated with cagrilintide; rotate sites consistently.
• Gallbladder events: Rapid weight loss can increase gallstone risk.
• Multi-source quality risk: Both compounds are investigational; sourcing quality variability is a major safety variable.
• Unknown interaction profile: Combined glucagon-pathway effects are theoretical and not clinically characterized.

Clinical Evidence Context

This stack is a four-receptor pathway-coverage model: GLP-1 appetite signaling, GIP metabolic support, glucagon-linked energy expenditure, and amylin-driven hindbrain satiety. It is broad mechanistically but still unproven as a combination.

Storage & Handling

Limiting factor: both compounds share similar refrigerated windows, but cagrilintide handling sensitivity (do not shake, discard cloudy solution) is typically the stricter operational constraint.

Cagrilintide + Retatrutide vs. CagriSema vs. Retatrutide Alone

Decision Guidance

• Choose Cagrilintide + Retatrutide only when prioritizing maximum theoretical receptor coverage and accepting highest complexity, cost, and uncertainty.
• Choose CagriSema when prioritizing combination evidence strength and more characterized safety data.
• Choose retatrutide alone when prioritizing strongest single-agent efficacy and simplest protocol logistics.

Related Stacking Protocols

CagriSema (Cagrilintide + Semaglutide)

The parent amylin + GLP-1 model with Phase 3 data and a late-2026 NDA decision timeline. View CagriSema stack.

Cagrilintide + Tirzepatide Stack

A middle-ground model between CagriSema and Cagrilintide + Retatrutide, pairing amylin signaling with dual incretin agonism while excluding glucagon agonism. View Cagrilintide + Tirzepatide stack.

Higher-Dose CagriSema (2.4/7.2 mg)

Novo Nordisk has also explored higher-dose semaglutide layering with cagrilintide as an alternate pharmaceutical escalation pathway.

Frequently Asked Questions - Cagrilintide + Retatrutide Stack

Sources & Research

1. Jastreboff AM, Kaplan LM, Frias JP, et al. "Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial." New England Journal of Medicine, 2023 Link.
2. Eli Lilly "Lilly's triple agonist, retatrutide, delivered weight loss of up to an average of 71.2 lbs along with substantial relief from osteoarthritis pain in first successful Phase 3 trial." Press Release, 2025 Link.
3. Garvey WT, et al. "Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity." New England Journal of Medicine, 2025 Link.
4. Lau DCW, Erichsen L, Francisco AM, et al. "Once-weekly cagrilintide for weight management in people with overweight and obesity." The Lancet, 2021 Link.
5. Enebo LB, Berthelsen KK, Kankam M, et al. "Safety, tolerability, pharmacokinetics, and pharmacodynamics of concomitant administration of multiple doses of cagrilintide with semaglutide 2.4 mg." The Lancet, 2021 Link.
6. Kruse T, Dahl K, Schaffer L, et al. "Development of Cagrilintide, a Long-Acting Amylin Analogue." Journal of Medicinal Chemistry, 2021 Link.
7. Giblin K, Kaplan LM, Somers VK, et al. "Retatrutide for the treatment of obesity, obstructive sleep apnea and knee osteoarthritis: Rationale and design of the TRIUMPH registrational clinical trials." Diabetes, Obesity and Metabolism, 2026 Link.
8. Fletcher MM, et al. "Structural and dynamic features of cagrilintide binding to calcitonin and amylin receptors." Nature Communications, 2025 Link.
9. Dutta D, et al. "Efficacy and Safety of Cagrilintide Alone and in Combination with Semaglutide (Cagrisema) as Anti-Obesity Medications: A Systematic Review and Meta-Analysis." Indian Journal of Endocrinology and Metabolism, 2024 Link.
10. ClinicalTrials.gov — (NCT05929066), (NCT06131437), (NCT05567796), (NCT05394519).

Related Protocols

Disclaimer